Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models
X. Cynthia(Washington University in St. Louis), Helen Piwnica‐Worms(Washington University in St. Louis)
Cited by 222
Related Papers
The Chk1 Protein Kinase and the Cdc25C Regulatory Pathways Are Targets of the Anticancer Agent UCN-01
|Journal of Biological Chemistry|2000|541
A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer
|Breast Cancer Research and Treatment|2012|107
CRL4<sup>CDT2</sup> Targets CHK1 for PCNA-Independent Destruction
|Molecular and Cellular Biology|2012|79
Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib
|Breast Cancer Research|2017|70
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies
|Cancer Chemotherapy and Pharmacology|2010|69